公司資料
4D Molecular Therapeutics, Inc. 股價、新聞與催化劑
- 股票代碼:
- FDMT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
13.84 USD (-3.28%)
收盤價
最後更新: 2026年10月1日
485M USD
市值
股價為何變動
最新監測到的公司動態為「4DMT to Host Investor Day on October 21, 2026」。相應的收盤價反應尚未產生。
公司概覽
Genetic Medicines Company
4D Molecular Therapeutics develops genetic medicines using an engineered AAV vector platform known as Therapeutic Vector Evolution. The technology is designed to select vectors for specific tissues and routes of administration rather than relying only on naturally occurring viral capsids.
4D-150 Retinal Franchise
4D-150 is an intravitreal dual-transgene therapy that expresses both aflibercept and an anti-VEGF-C molecule. It is being developed for wet age-related macular degeneration and diabetic macular edema with the goal of providing durable control after a single administration.
Late-Stage Ophthalmology Development
The 4FRONT pivotal program evaluates 4D-150 in wet age-related macular degeneration, while a separate Phase 3 strategy is advancing in diabetic macular edema. These studies position ophthalmology as the company's principal near-term value driver.
Broader Retinal Pipeline
4D-175 is being developed for geographic atrophy and extends the platform beyond VEGF-driven retinal disease. The program reflects the company's ability to design vectors and payloads for additional degenerative eye conditions.
Aerosol Gene Therapy for Cystic Fibrosis
4D-710 is an inhaled gene therapy intended to deliver a functional CFTR transgene to airway cells. The program targets people with cystic fibrosis who may not benefit adequately from existing CFTR modulators.
未來催化劑
- Initiation of a Phase 3 study of 4D-150 in diabetic macular edema in the third quarter of 2026.
- Two-year SPECTRA data for 4D-150 in diabetic macular edema in the fourth quarter of 2026.
- Updated AEROW clinical data for 4D-710 in cystic fibrosis in the fourth quarter of 2026.
- Topline results from the 4FRONT-1 pivotal study of 4D-150 in the second quarter of 2027.
- Topline results from the 4FRONT-2 pivotal study of 4D-150 in the second half of 2027.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。